search
Back to results

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

Primary Purpose

COVID-19

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Low-dose placebo (18-59 years) & Two dose regimen
Low-dose placebo (18-59 years) & Three dose regimen
High-dose placebo (18-59 years) & Two dose regimen
High-dose placebo (18-59 years) & Three dose regimen
Low-dose placebo (60-85 years) & Two dose regimen
Low-dose placebo (60-85 years) & Three dose regimen
High-dose placebo (60-85 years) & Two dose regimen
High-dose placebo (60-85 years) & Three dose regimen
Sponsored by
Jiangsu Province Centers for Disease Control and Prevention
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for COVID-19 focused on measuring Safety, Immunogenicity, COVID-19 Vaccine, Recombinant vaccine

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged 18 years and above.
  • Able to understand the content of informed consent and willing to sign the informed consent.
  • Able and willing to complete all the secluded study process during the whole study follow-up period (about 7 months).
  • Axillary temperature ≤37.0℃.
  • General good health as established by medical history and physical examination.

Exclusion Criteria:

First dose exclusion criteria:

  • Positive serum immunoglobulin M (IgM) and IgG to the SARS-CoV-2.
  • A Known History of HIV infection
  • Family history of seizure, epilepsy, brain or mental disease.
  • Participant that has an allergic history to any ingredient of vaccines.
  • Woman who is pregnant, breast-feeding or positive in pregnancy test on day of enrollment, or is planning to be pregnant during the next 6 months.
  • Any acute fever disease or infections.
  • Have a medical history of SARS.
  • Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and not well-controlled.
  • Major chronic illness, such as asthma, diabetes, or thyroid disease, and not well-controlled.
  • Hereditary angioneurotic edema or acquired angioneurotic edema.
  • Urticaria in last one year.
  • Asplenia or functional asplenia.
  • Platelet disorder or other bleeding disorder may cause injection contraindication.
  • Faint at the sight of blood or needles.
  • Prior administration of immunodepressant or corticosteroids, antianaphylactics treatment, cytotoxic treatment in last 6 months.
  • Prior administration of blood products in last 4 months.
  • Prior administration of other research medicines in last 1 month.
  • Prior administration of attenuated vaccine in last 1 month.
  • Prior administration of subunit vaccine or inactivated vaccine in last 14 days.
  • Being treated for tuberculosis.
  • Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives.

Exclusion criteria for subsequent doses:

  • Patients with severe allergic reactions after the previous dose of vaccination;
  • Patients with serious adverse events causally related to the previous dose of vaccination.

Sites / Locations

  • Jiangsu Provincial Center for Diseases Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm 16

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Low-dose vaccine (18-59 years) & Two dose regimen

Low-dose vaccine (18-59 years) & Three dose regimen

High-dose vaccine (18-59 years) & Two dose regimen

High-dose vaccine (18-59 years) & Three dose regimen

Low-dose vaccine (60-85 years) & Two dose regimen

Low-dose vaccine (60-85 years) & Three dose regimen

High-dose vaccine (60-85 years) & Two dose regimen

High-dose vaccine (60-85 years) & Three dose regimen

Low-dose placebo (18-59 years) & Two dose regimen

Low-dose placebo (18-59 years) & Three dose regimen

High-dose placebo (18-59 years) & Two dose regimen

High-dose placebo (18-59 years) & Three dose regimen

Low-dose placebo (60-85 years) & Two dose regimen

Low-dose placebo (60-85 years) & Three dose regimen

High-dose placebo (60-85 years) & Two dose regimen

High-dose placebo (60-85 years) & Three dose regimen

Arm Description

two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

two doses of placebo at the schedule of day 0, 21.

three doses of placebo at the schedule of day 0, 14, 28.

two doses of placebo at the schedule of day 0, 21.

three doses of placebo at the schedule of day 0, 14, 28.

two doses of placebo at the schedule of day 0, 21.

three doses of placebo at the schedule of day 0, 14, 28.

two doses of placebo at the schedule of day 0, 21.

three doses of placebo at the schedule of day 0, 14, 28.

Outcomes

Primary Outcome Measures

Geometric mean (GMT) of specific antibody
Geometric mean (GMT) of specific antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein Receptor-binding domain(S-RBD) protein (ELISA)
The incidence of adverse reaction (AR)
The incidence of adverse reaction (AR)

Secondary Outcome Measures

The incidence of adverse events (AE)
The incidence of adverse events (AE)
The incidence of severe adverse events (SAE)
The incidence of severe adverse events (SAE)
The incidence of serious adverse events
The incidence of serious adverse events
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
The positive conversion rate of S-RBD protein-specific antibody
The positive conversion rate of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Geometric mean fold increase (GMI) of S-RBD protein-specific antibody
Geometric mean fold increase (GMI) of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization test)
Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies
Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies (eucivirus and pseudovirus neutralization assays)

Full Information

First Posted
November 19, 2020
Last Updated
May 31, 2022
Sponsor
Jiangsu Province Centers for Disease Control and Prevention
Collaborators
West China Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04640402
Brief Title
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)
Official Title
A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 17, 2020 (Actual)
Primary Completion Date
February 18, 2021 (Actual)
Study Completion Date
November 23, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu Province Centers for Disease Control and Prevention
Collaborators
West China Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with different immunization procedures (0, 21 days and 0, 14, 28 days) and doses (20μg/40μg).
Detailed Description
This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) . The phase Ⅱ clinical trials designed 8 research group, including two immunization procedures (0, 21 days and 0, 14, 28 days), two doses (20μg/0.5ml, 40μg/1.0ml) and two ages group (adults and elder): Each group including 120 participants. Vaccination or placebo group will be randomly assigned to receive in a 5:1 ratio, 960 in total.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
Safety, Immunogenicity, COVID-19 Vaccine, Recombinant vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
960 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low-dose vaccine (18-59 years) & Two dose regimen
Arm Type
Experimental
Arm Description
two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Arm Title
Low-dose vaccine (18-59 years) & Three dose regimen
Arm Type
Experimental
Arm Description
three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Arm Title
High-dose vaccine (18-59 years) & Two dose regimen
Arm Type
Experimental
Arm Description
two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Arm Title
High-dose vaccine (18-59 years) & Three dose regimen
Arm Type
Experimental
Arm Description
three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Arm Title
Low-dose vaccine (60-85 years) & Two dose regimen
Arm Type
Experimental
Arm Description
two doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Arm Title
Low-dose vaccine (60-85 years) & Three dose regimen
Arm Type
Experimental
Arm Description
three doses of low-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Arm Title
High-dose vaccine (60-85 years) & Two dose regimen
Arm Type
Experimental
Arm Description
two doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Arm Title
High-dose vaccine (60-85 years) & Three dose regimen
Arm Type
Experimental
Arm Description
three doses of high-dose Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Arm Title
Low-dose placebo (18-59 years) & Two dose regimen
Arm Type
Placebo Comparator
Arm Description
two doses of placebo at the schedule of day 0, 21.
Arm Title
Low-dose placebo (18-59 years) & Three dose regimen
Arm Type
Placebo Comparator
Arm Description
three doses of placebo at the schedule of day 0, 14, 28.
Arm Title
High-dose placebo (18-59 years) & Two dose regimen
Arm Type
Placebo Comparator
Arm Description
two doses of placebo at the schedule of day 0, 21.
Arm Title
High-dose placebo (18-59 years) & Three dose regimen
Arm Type
Placebo Comparator
Arm Description
three doses of placebo at the schedule of day 0, 14, 28.
Arm Title
Low-dose placebo (60-85 years) & Two dose regimen
Arm Type
Placebo Comparator
Arm Description
two doses of placebo at the schedule of day 0, 21.
Arm Title
Low-dose placebo (60-85 years) & Three dose regimen
Arm Type
Placebo Comparator
Arm Description
three doses of placebo at the schedule of day 0, 14, 28.
Arm Title
High-dose placebo (60-85 years) & Two dose regimen
Arm Type
Placebo Comparator
Arm Description
two doses of placebo at the schedule of day 0, 21.
Arm Title
High-dose placebo (60-85 years) & Three dose regimen
Arm Type
Placebo Comparator
Arm Description
three doses of placebo at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Intervention Description
18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Intervention Description
18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Intervention Description
18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Intervention Description
18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Intervention Description
60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Intervention Description
60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Intervention Description
60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Intervention Description
60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
Low-dose placebo (18-59 years) & Two dose regimen
Intervention Description
18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
Low-dose placebo (18-59 years) & Three dose regimen
Intervention Description
18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
High-dose placebo (18-59 years) & Two dose regimen
Intervention Description
18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
High-dose placebo (18-59 years) & Three dose regimen
Intervention Description
18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
Low-dose placebo (60-85 years) & Two dose regimen
Intervention Description
60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
Low-dose placebo (60-85 years) & Three dose regimen
Intervention Description
60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
Intervention Type
Biological
Intervention Name(s)
High-dose placebo (60-85 years) & Two dose regimen
Intervention Description
60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
Intervention Type
Biological
Intervention Name(s)
High-dose placebo (60-85 years) & Three dose regimen
Intervention Description
60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
Primary Outcome Measure Information:
Title
Geometric mean (GMT) of specific antibody
Description
Geometric mean (GMT) of specific antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein Receptor-binding domain(S-RBD) protein (ELISA)
Time Frame
1 months after immunization in each study group
Title
The incidence of adverse reaction (AR)
Description
The incidence of adverse reaction (AR)
Time Frame
0 to 7 days after vaccination in each study group
Secondary Outcome Measure Information:
Title
The incidence of adverse events (AE)
Description
The incidence of adverse events (AE)
Time Frame
0 to 28 days after vaccination in each study group
Title
The incidence of severe adverse events (SAE)
Description
The incidence of severe adverse events (SAE)
Time Frame
0 to 28 days after vaccination in each study group
Title
The incidence of serious adverse events
Description
The incidence of serious adverse events
Time Frame
6 months after vaccination in each study group
Title
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies
Description
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Time Frame
1 months after immunization in each study group
Title
The positive conversion rate of S-RBD protein-specific antibody
Description
The positive conversion rate of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Time Frame
14 days, 30 days after immunization in each study group
Title
Geometric mean fold increase (GMI) of S-RBD protein-specific antibody
Description
Geometric mean fold increase (GMI) of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Time Frame
14 days, 30 days after immunization in each study group
Title
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies
Description
Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Time Frame
14 days after immunization in each study group
Title
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody
Description
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization test)
Time Frame
14 days, 30 days after immunization in each study group
Title
Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies
Description
Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies (eucivirus and pseudovirus neutralization assays)
Time Frame
14 days, 30 days after immunization in each study group
Other Pre-specified Outcome Measures:
Title
The consistency analysis of the specific antibody and the specific neutralizing antibody
Description
The consistency analysis of the specific antibody (ELISA) and the specific neutralizing antibody (euvirus and pseudovirus neutralization assays) against SARS-CoV-2 S-RBD protein
Time Frame
1 months after immunization in each study group
Title
The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody
Description
The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups
Time Frame
1 months after immunization in each study group
Title
The persistence (GMT，GMI，positive conversion rate) of specific antibodies
Description
The persistence (GMT，GMI，positive conversion rate) of specific antibodies against SARS-CoV-2 S-RBD protein
Time Frame
6 months after vaccination in each study group
Title
Subtypes of immunoglobulin G (IgG) antibodies
Description
Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group
Time Frame
1 months after immunization in each study group

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged 18 years and above. Able to understand the content of informed consent and willing to sign the informed consent. Able and willing to complete all the secluded study process during the whole study follow-up period (about 7 months). Axillary temperature ≤37.0℃. General good health as established by medical history and physical examination. Exclusion Criteria: First dose exclusion criteria: Positive serum immunoglobulin M (IgM) and IgG to the SARS-CoV-2. A Known History of HIV infection Family history of seizure, epilepsy, brain or mental disease. Participant that has an allergic history to any ingredient of vaccines. Woman who is pregnant, breast-feeding or positive in pregnancy test on day of enrollment, or is planning to be pregnant during the next 6 months. Any acute fever disease or infections. Have a medical history of SARS. Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and not well-controlled. Major chronic illness, such as asthma, diabetes, or thyroid disease, and not well-controlled. Hereditary angioneurotic edema or acquired angioneurotic edema. Urticaria in last one year. Asplenia or functional asplenia. Platelet disorder or other bleeding disorder may cause injection contraindication. Faint at the sight of blood or needles. Prior administration of immunodepressant or corticosteroids, antianaphylactics treatment, cytotoxic treatment in last 6 months. Prior administration of blood products in last 4 months. Prior administration of other research medicines in last 1 month. Prior administration of attenuated vaccine in last 1 month. Prior administration of subunit vaccine or inactivated vaccine in last 14 days. Being treated for tuberculosis. Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives. Exclusion criteria for subsequent doses: Patients with severe allergic reactions after the previous dose of vaccination; Patients with serious adverse events causally related to the previous dose of vaccination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fengcai Zhu, Doctor
Organizational Affiliation
Jiangsu Provincial Center for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jiangsu Provincial Center for Diseases Control and Prevention
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China

12. IPD Sharing Statement

Learn more about this trial

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

We'll reach out to this number within 24 hrs